THE Magnifying LeNS: LEARNING NEW SCIENCE QUARTERLY

JANUARY 2022
Navigating Biomarker Testing Issues

Due to the increasing number of approved targeted therapies for the treatment of lung cancer, clinical guidelines recommend that every patient receive comprehensive biomarker testing. Despite the importance of comprehensive biomarker testing, some people with lung cancer can face barriers that make it difficult to either obtain appropriate testing, or use the results of their testing to make informed treatment decisions.
In 2021, one of GO2 Foundation’s priorities continued to be bringing lung cancer education and empowerment to patients to help ensure equitable healthcare. One of the tools GO2 Foundation used and continues to implement is the Small Cell Lung Cancer Initiative in which the overarching objective is to educate, support, and engage those affected by SCLC in an ongoing and consistent manner, and to bridge gaps in care and meet needs through outreach and authentic listening, expanding resources, and building community.
Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment options targeting mutations that were previously unavailable for patients. Additionally, new immunotherapy options were approved, giving more variety and treatment options as well as post-surgery options.
Identification of Chemoradiation Response Mediators in Non-Small Cell Lung Cancer via Circulating Tumor DNA Analysis

A combination of chemotherapy and radiation therapy is the backbone of treatment for non-small cell lung cancer that has spread to the lymph nodes in patients who are not candidates for surgery. Although chemoradiation therapy has the potential to be curative, most patients relapse after treatment. Furthermore, many patients are likely over-treated with higher than necessary radiation doses because there are currently no proven approaches to identify which patients could benefit from more or less treatment.
About Us

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

DONATE TODAY!
Contact Us

Email: info@go2foundation.org  |  HelpLine: 1-800-298-2436 (9-5 EDT)

Washington, DC
Phone: 202-463-2080

San Francisco Bay Area
Phone: 650-598-2857
THANK YOU TO OUR SPONSORS

Genentech
A Member of the Roche Group

REGENERON

SANOFI
GENZYME

Bristol Myers Squibb

NOVARTIS